I checked my pay stub this morning, protein shake in hand, and stared at the insurance line like it owed me money. It does. Millions of us do — more than 165 million Americans rely on employer-sponsored coverage, and in 2027 a big chunk of our paychecks may quietly go to premiums.
Mercer, a consulting firm that tracks workplace benefits, projects healthcare costs per employee will increase 8.2% in 2027 — the steepest jump since 2003 and the fifth straight year of elevated costs, based on a survey of 1,800 U.S. employers. At the same time, President Trump is selling a new Medicaid drug-pricing agreement covering all 50 states as the fix for prescription costs. Do the two cancel each other out? Not exactly. Let me break it down the way I break down a training block: what it is, what it costs, what you do.
The Why: Your Paycheck Math Is Changing
Here’s the part that actually lands on you. Workers with family coverage paid an average of about $6,850 toward premiums last year. Mercer found that two-thirds of companies with at least 500 employees plan to raise workers’ premium contributions in 2027, and almost half plan to change their medical plans in ways that can push more cost onto employees — higher deductibles, higher copays, a bigger share of the premium. The 8.2% is the employer-side total; how much of it you personally feel depends on what your company absorbs.
The What’s Driving It
Mercer points to hospital consolidation, reduced government spending, and expensive new treatments — including cancer drugs and GLP-1 (a class of weight-loss and diabetes drugs, including Ozempic and Mounjaro). GLP-1 use alone, by Mercer chief actuary Sunit Patel’s estimate, accounts for one percentage point of the projected 2027 cost growth. AI-enabled medical billing is on the list too. Translation: the price of healthcare isn’t rising because of one villain. It’s a lot of small arrows, all pointing up.
The Other Story: Trump’s Medicaid Deal
On September 18, Trump announced that all 50 state Medicaid programs would join the administration’s GENEROS Medicaid Payment Model. CMS says all 50 states, the District of Columbia, and Puerto Rico applied; 40 states and Puerto Rico have signed. The idea: pharmaceutical makers give rebates so Medicaid’s final price on selected drugs doesn’t exceed a most-favored-nation benchmark based on prices in other developed countries. The White House says it covers hundreds of drugs, including cancer, diabetes, and asthma medicines.
The numbers the administration is touting: 26 major drugmakers — about 90% of the branded U.S. market — have agreed to most-favored-nation pricing, projected to save more than $600 billion; the Medicaid agreements could unlock nearly $65 billion in savings over the next decade. TrumpRx, the administration’s prescription platform, reportedly generated over $700 million in savings and covers more than 1,000 branded and generic medicines. Medicaid has also already received one million free prescriptions of Eliquis, a widely used heart medication. CMS itself estimates the model could save $64.3 billion in taxpayer dollars over 10 years.
Here’s the honest part: those are administration estimates, not realized savings. Analysts note the real impact depends on which manufacturers participate, which drugs are included, and how deep the rebates go — Medicaid already gets some of the deepest drug discounts in the system, so the extra room varies a lot from one drug to the next.
And the two stories cover different ground. The Medicaid deal targets prescription drug spending in a specific government program. The Mercer projection is about employer-sponsored insurance — the plan on your pay stub. One is policy; the other is your benefits statement. Both are real, and they don’t offset each other on your household budget.
Why the Midterms Keep Showing Up
Healthcare affordability is a live election issue. A January KFF poll found 66% of Americans worried about affording healthcare for themselves and their families, and 55% said their costs had increased during the previous year. In April, 64% of adults still said they were worried. Nine in 10 voters said healthcare costs would influence how they vote in the 2026 midterms — 55% said it would have a major impact on whether they vote, 61% on which party they support. Arkansas Governor Sarah Huckabee Sanders called the Medicaid deal a potential “generational change in our country’s health care.” That’s the frame Republicans are selling. Whether projected savings become real savings for beneficiaries and taxpayers comes down to how the program actually runs.
What This Means for You
Not financial or medical advice — just what the numbers say about the next open enrollment. If you have employer coverage:
- Read the new plan documents before you sign anything. A “flat” premium can still mean a higher deductible or higher copays. Compare out-of-pocket maximums side by side, not just the monthly line.
- Check the pharmacy side of your plan. Formulary changes — which drugs are covered and at what tier — can quietly shift your costs more than the premium itself.
- Treat the raise line as part of the equation. If benefits eat more of your employer’s compensation budget, your salary growth may feel slower than the headline. Ask what changed, in writing, during your review.
None of this is a reason to skip the gym. It’s a reason to know your own numbers before someone else’s spreadsheet decides them for you.
Your Move:
- Pull this year’s benefits summary tonight and find your out-of-pocket maximum — takes 5 minutes, and it’s the number that caps your worst-case month.
- Before open enrollment, list your top 3 prescriptions and check whether they’re on next year’s formulary and at what tier.
- At your next pay review, ask one direct question: “What’s changing in my benefits, and what does it change for my take-home?”
Do those three, and 2027 becomes a number you understand instead of a surprise in your bank app. Sustainable, right? That’s all we ever ask.